Evidence review

Retatrutide research

Retatrutide is an investigational GLP-1, GIP, and glucagon receptor agonist with peer-reviewed Phase 2 evidence in obesity and type 2 diabetes.

Obesity Phase 2

The highest-dose arm reported 24.2% mean body-weight reduction at 48 weeks.

Broader metabolic research

Published studies also examine glycemic outcomes, liver fat, and body composition.

Not approved

Retatrutide remains an investigational product without an FDA-approved label.

Mechanism and development status

Retatrutide activates three metabolic receptor systems in one molecule: GLP-1, GIP, and glucagon. That mechanism distinguishes it from approved single- and dual-agonist medicines, but it does not establish clinical superiority.

Peer-reviewed human evidence

A Phase 2 obesity trial reported dose-related weight reduction over 48 weeks.
A separate Phase 2 type 2 diabetes trial reported glycemic and weight outcomes.
Published analyses examine liver-fat and body-composition outcomes in selected study populations.

Evidence limits

Retatrutide has no approved consumer label. Trial material, monitoring, and participant selection cannot validate third-party research products or self-directed protocols.